IGHE and asthma: This deficient production of type I interferons in asthmatic patients, involving an inhibitory effect of the IgE crosslinking in pDCs has been further examined in a recent study which found that treatment with omalizumab (a mAb that blocks IgE) reduced asthma exacerbations and improved IFN-α responses to rhinovirus (RV).